

Innovative Medicines Initiative

StemBANCC: Shifting Drug Discovery Paradigms

Dr Zameel Cader University of Oxford




Drug discovery is failing: increasing investment but no increase in new medicines

Alzheimer's Disease: 35.6 million people worldwide in 2010 with global cost of \$605 billion [Alzheimer's Disease International]

Not a single disease modifying treatment for Alzheimer's or any other neurodegenerative disorder








The StemBANCC Project







StemBANCC

- Consortium of 10 Pharma and 23 Academic/SME
- Start date: Autumn 2012
- Duration: 5 years
- Total cost: €55.6 million
- Project coordinator: Martin Graf,
 F. Hoffmann-La Roche Ltd
- Managing entity: Zameel Cader, University of Oxford
- www.stembancc.org








StemBANCC









- Effective project coordination team and steering committee with effective communication across the consortium
- Strong public engagement with successful press briefing and worldwide media coverage at launch
- A StemBANCC website and intranet for the consortium: central source for information and documents including >28 standard operating
 protocols etc







ADVANCING SCIENCE AND IMPLEMENTING NOVEL, CUTTING EDGE TECHNOLOGIES

StemBANCC aims to provide well characterised patient derived induced pluripotent stem cell lines and associated biomaterials in an accessible and sustainable bio-bank. StemBANCC also aims to demonstrate proof of concept for the utility of induced pluripotent stem cells in drug discovery for hard-to-treat disorders.

STEMBANCC - AN OVERVIEW



CONCEPT: StemBANCC is a large-scale, 5 year academic-industry partnership in the area of stem cell research. It brings a consortium of 35 partners together who share their experience and collaborate in 12 work packages. It is a collaborative project between pharmaceutical companies, research institutions and small and medium enterprises (SMEs) to exploit the rich expertise across sectors and enhance knowledge transfer between academia and industry for patient benefit.

Read more

NEWS & EVENTS

Open position in StemBANCC

Postdoctoral Research Assistant in Stem Cells at University of Oxford, Nuffield Department of Clinical Neurosciences

FACTS & FIGURES

- Stem cells for biological assays of novel drugs and predictive toxicology
- Total cost: € 55.6 million



Q







- Reprogramming method and workflow agree with first reference iPS produced and distributed
- Governance framework for iPSC access agreed and iPSC will be accessible to the International community: Academia, SME and Pharma
- Multi-centre, multi-national ethics approval granted
- Patient recruitment underway (>100 subjects) and accelerating with minimal dataset agreed





Subject Recruitment



Oxford



Luebeck



London





Copenhagen











- >60 subject reprogrammings in progress/completed: focus on monogenic forms of disease
- Technology Transfers / Trainings ongoing in iPS cultivation and differentiation
- *Regular WebEx presentations to disseminate knowledge and experience*
- Development of standardized differentiation protocols validated in multiple labs, e.g.:
 - nociceptive neurons
 - cortical glutamatergic
 - mid-brain dopaminergic neurons
 - podocyte differentiation protocol established and patented






Differentiation at Oxford




PNS


Day 15: Nociceptive Neurons




Day 60: Nociceptive Neurons



Schwann Cells - Nociceptive Neurons



CNS







Dr Zameel Cader Institute of Molecular Medicine John Radcliffe Hospital University of Oxford Oxford OX3 9DU

zameel.cader@ndcn.ox.ac.uk





IMI Stakeholder Forum – 21 May 2014 - Brussels